Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD)

Next Previous
X
Search
Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LP 0145 (Primary)
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors LEO Pharma

    • Most Recent Events

    • 13 Oct 2023 According to a LEO Pharma media release, efficacy and safety data from this study will be presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress from the 11th to the 14th of October in Berlin, Germany.
    • 18 Mar 2023 Primary endpoint (Change in EASI score from baseline to Week 16) has been met, as per the results presented in the Leo Pharma Media Release.
    • 18 Mar 2023 Results assessing safety and efficacy of LEO 138559 in patients with moderate-to-severe atopic dermatitis, presented at 2023 American Academy of Dermatology (AAD) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top